Phenformin

From WikiMD's WELLNESSPEDIA

(Redirected from Insoral)

Phenformin.svg

Phenformin is a biguanide class antidiabetic drug that was introduced in the 1950s for the treatment of type 2 diabetes. It was withdrawn from most markets in the late 1970s due to its association with a high risk of lactic acidosis.

History[edit]

Phenformin was developed in the 1950s and was widely used as an oral hypoglycemic agent. It was marketed under various brand names and was considered effective in lowering blood glucose levels in patients with type 2 diabetes. However, by the late 1970s, it became evident that phenformin was associated with a significant risk of lactic acidosis, a potentially fatal condition. As a result, it was withdrawn from the market in many countries.

Mechanism of Action[edit]

Phenformin works by decreasing hepatic gluconeogenesis and increasing peripheral glucose uptake. It also enhances the sensitivity of insulin receptors, thereby improving glucose utilization in the body. Unlike sulfonylureas, phenformin does not stimulate insulin secretion from the pancreas.

Side Effects[edit]

The most serious side effect of phenformin is lactic acidosis, which can be fatal. Other side effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Due to its severe side effect profile, phenformin is no longer used in clinical practice.

Withdrawal from Market[edit]

The association of phenformin with lactic acidosis led to its withdrawal from the market in many countries. In the United States, the Food and Drug Administration (FDA) withdrew phenformin in 1977. Other countries followed suit, and it is now rarely used, having been replaced by other biguanides like metformin, which has a much lower risk of lactic acidosis.

Current Status[edit]

Phenformin is no longer widely available or used in clinical practice. However, it remains a subject of research, particularly in the context of its potential anticancer properties. Some studies have suggested that phenformin may have a role in inhibiting the growth of certain types of cancer cells, although this is still under investigation.

See Also[edit]

References[edit]


External Links[edit]

-


Diabetes Drug Stub
This article about a diabetes drug is a stub. You can help WikiMD by expanding it.
Related topics Diabetes mellitus · Insulin · Hypoglycemia · Hyperglycemia


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.